Drug intelligence / Profile preview

ARGX-220

Development stage: Preclinical
Lead developer: argenx
Modality: Antibody-Based Therapeutics

Overview

ARGX-220 is a first-in-class experimental antibody therapy developed by argenx. It is described as a "sweeping antibody," but its precise molecular target and mechanism of action have not yet been publicly disclosed. The drug is part of argenx's Immunology Innovation Program, which focuses on developing novel therapies for immune-mediated diseases. As of early 2025, ARGX-220 remains in preclinical development, with investigational new drug (IND) applications planned to be filed by the end of 2025[2][4][7]. No clinical data or specific disease indications have been published.

Beyond the preview

Go deeper on ARGX-220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARGX-220.

Explore the full profile